NOF Corporation
Notice Regarding Revision of Full-Year Consolidated Earnings Forecast and Year-End Dividend Forecast for Fiscal Year Ending March 2026
Sales have been revised upward by 21 billion yen to 260.5 billion yen, ordinary income increased by 12 billion yen to 49.5 billion yen, and net income attributable to owners of parent has been revised upward by 12 billion yen to 39.4 billion yen. Dividends are planned to be increased to 61 yen annually.
Key Figures
- Sales: 260,500 million yen (0.8% increase from previous forecast)
- Ordinary Income: 49,500 million yen (2.5% increase from previous forecast)
- Annual Dividend: 61 yen 00 sen (9 yen increase from previous forecast)
AI要約
Details of Earnings Forecast Revision
For the fiscal year ending March 2026, the consolidated earnings forecast has been revised to sales of 260,500 million yen, an increase of 2,100 million yen from the previous forecast, ordinary income of 49,500 million yen, up 1,200 million yen, and net income attributable to owners of parent of 39,400 million yen, up 1,200 million yen. Operating income is unchanged from the previous forecast at 46,000 million yen. Net income per share has increased to 171.21 yen from the prior forecast of 166.18 yen.
Reasons for Revision and Dividend Forecast
While expecting decreased demand due to delayed market deployment of DDS pharmaceutical raw materials in the pharmaceutical, medical, and healthcare business, the full-year sales and profits are expected to exceed previous forecasts due to progress in certain transactions associated with early deployment of defense-related products in the chemical products business. The revision of exchange rates has also contributed to the earnings uplift. The year-end dividend forecast has been raised from 26 yen to 35 yen, a 9 yen increase, resulting in an annual dividend of 61 yen, which is a 9 yen increase from the previous forecast and a 16 yen increase from the previous fiscal year.
